BRAINSTORM CELL THERAPEUTICS's ticker is and the CUSIP is 10501E951. A total of 4 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,121 | -90.3% | 106 | 0.0% | 0.00% | -88.9% |
| Q2 2023 | $21,836 | -98.9% | 106 | -98.0% | 0.02% | -94.0% |
| Q4 2021 | $2,071,000 | +27.4% | 5,177 | +5.1% | 0.30% | +36.8% |
| Q3 2021 | $1,626,000 | -9.2% | 4,928 | +4.6% | 0.22% | -13.0% |
| Q2 2021 | $1,791,000 | +5.7% | 4,713 | +6.5% | 0.25% | -23.3% |
| Q1 2021 | $1,694,000 | +57.9% | 4,424 | +86.6% | 0.33% | +60.2% |
| Q4 2020 | $1,073,000 | -85.7% | 2,371 | -46.6% | 0.21% | -81.6% |
| Q3 2020 | $7,519,000 | -77.3% | 4,444 | -52.4% | 1.12% | -83.2% |
| Q2 2020 | $33,173,000 | +1669.2% | 9,329 | +130.9% | 6.66% | +754.8% |
| Q1 2020 | $1,875,000 | +109.7% | 4,041 | +93.5% | 0.78% | +214.1% |
| Q4 2019 | $894,000 | -12.0% | 2,088 | -19.9% | 0.25% | -54.7% |
| Q3 2019 | $1,016,000 | +91.0% | 2,606 | +31.0% | 0.55% | -18.2% |
| Q2 2019 | $532,000 | – | 1,990 | – | 0.67% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 2,371 | $1,073,000 | 0.21% |
| GROUP ONE TRADING, L.P. | 216,400 | $979,000 | 0.00% |
| SIMPLEX TRADING, LLC | 472 | $213,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |